Business Wire

Ferring Announces Recipients of Innovation Grants Program 2017-2018

Del

Ferring Pharmaceuticals today announced the recipients of the 2017-2018 Innovation Grants Program, an annual initiative of the Ferring Research Institute (FRI) based in San Diego. This global program supports research in the fields of reproductive medicine and women’s health, urology, gastroenterology, hepatology, and endocrinology.

“The quality of applications received in response to the 2017-2018 Ferring Innovation Grants call for proposals was outstanding. We have funded programs that we believe represent the leading edge of research in their therapeutic fields, and very much look forward to seeing the outcome of the innovative projects proposed by this year’s grant awardees,” said Keith James, President Ferring Research Institute, Senior Vice President Research and Development.

Now in its fifth year, the Innovation Grants Program received 300 submissions. Each submission was reviewed for its scientific merit, and a short list of finalists were invited to submit more detailed applications for consideration. A total of 13 projects were chosen to receive grant funding from Ferring this year. In addition to the United States, projects have been funded in Canada, the United Kingdom, Australia, and Portugal. This year’s recipients, together with the grant titles, are:

  • Stéphane Bolduc - CHU de Québec - Université Laval Research Center
    Identify protein(s) secreted by urothelial cell carcinoma (UCC) involved in modification of tumor-associated stroma by activation of Cancer-Associated Fibroblasts (CAF).
  • Marcello Costa - Flinders University
    Enteric neuropeptides modulation of colonic motility in health and disease
  • Warren Foster - McMaster University
    Evaluation of a novel therapeutic intervention for the management of endometriosis in a mouse model
  • Andrew Horne - University of Edinburgh
    Targeting TGFβ-1 with an extracellular peptide inhibitor to treat women with peritoneal endometriosis
  • K. Joseph Hurt - University of Colorado School of Medicine
    Adiponectin receptor regulation of myometrial contractility suggests novel therapeutic targets to augment uterine quiescence and prevent preterm birth
  • Ursula Kaiser - Brigham and Women's Hospital, Harvard Medical School
    Differential modulation of LH and FSH by GnRH analogs for improved treatment of reproductive disorders
  • Sarah Marshall - Monash University
    Exploring novel therapies for preeclampsia: the role of soluble prorenin receptor on vasculature function
  • Kathryn Meier - Washington State University
    FSH receptor as a therapeutic target in prostate cancer
  • Victor Navarro - Brigham and Women's Hospital, Harvard Medical School
    Targeting the Kappa Opioid Receptor to Regulate LH Pulses in PCOS Patients
  • Willis Samson - Saint Louis University School of Medicine
    A Novel Ligand (Adropin) – Receptor (GPR19) Handshake: Implications for the Control of Growth Hormone Secretion
  • John Taylor - Kansas University Medical Center
    The Role of d-Dopachrome Tautomerase in Bladder Cancer Tumorigenesis
  • Suraj Unniappan - University of Saskatchewan
    Nesfatin-1 and Nesfatin-1-Like Peptide Regulation of Growth and Stress Hormones: Novel Targets for Endocrine Diseases
  • Henrique Veiga-Fernandes - Champalimaud Foundation
    Activation of type 3 Innate Lymphoid Cells and innate IL-22 secretion via RET signaling for Inflammatory Bowel Disease treatment

About Ferring Pharmaceuticals:

Ferring Pharmaceuticals is a research-driven, speciality biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women’s health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years. Today, over one third of the company’s research and development investment goes towards finding innovative and personalised healthcare solutions to help mothers and babies, from conception to birth. Founded in 1950, Ferring now employs approximately 7,000 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.

Learn more at www.ferring.com and @Ferring, or connect with us on Facebook and LinkedIn.

About Ferring Research Institute Inc:

Located in San Diego, California Ferring Research Institute Inc. (FRI) is a global therapeutics research center for Ferring Pharmaceuticals. FRI is committed to delivering a pipeline of innovative therapies which improve the lives of patients in the areas of reproductive medicine and women’s health, urology, gastroenterology and hepatology. For more detailed information please visit www.ferring-research.com .

Contact information

Ferring Corporate Communications Team:
Lindsey Rodger
Senior Manager, Corporate Communications
+41 58 451 40 23 (direct)
+41 79 191 0486 (mobile)
lindsey.rodger@ferring.com
or
Bhavin Vaid
Head of Corporate Communications
+41 58 301 09 52 (direct)
+41 79 191 06 32 (mobile)
bhavin.vaid@ferring.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Telna Launches New eSIM Solution at MWC Barcelona 201924.2.2019 00:00:00Pressemelding

Telna, a vertically integrated Network-as-a-Service (NaaS) provider of global end-to-end connectivity solutions, today is adding eSIM technology to its platform. The new resilient and efficient eSIM architecture will be showcased at Mobile World Congress Barcelona 2019, from February 25th - February 28th at Telna’s booth in Hall 1, Stand 1B80. “eSIM technology is another example of a global trend in digital transformation set to disrupt cellular connectivity,” says Gregory Gundelfinger, CEO of Telna. “Our customers now have access to both Consumer and IoT/M2M eSIM that is bundled with the rest of our software-defined network services.” eSIM is an embedded SIM card, meaning there is no physical SIM card and no physical swapping of SIM cards. It's easy to add data plans and is endorsed by the GSMA. “The virtualization of the SIM card removes one of the largest barriers when switching between networks, the physical SIM card,” says Gundelfinger. The Telna eSIM allows users to access their

Hilton Launches New Brand, Signia Hilton, Delivering Sophisticated Travel While Reimagining Meetings and Events22.2.2019 17:00:00Pressemelding

Hilton (NYSE: HLT) today announced the launch of Signia Hilton, its dynamic, new meetings-and-events-focused brand. The portfolio of hotels is setting out to transform the industry for meeting professionals and sophisticated business travelers by infusing state-of-the-art technology and design into every aspect of the guest experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190222005071/en/ The brand further reinforces Hilton’s commitment to innovation that meets the evolving needs of today’s travelers and will bring premium experiences to top urban and resort destinations around the world. “In our 100th year of hospitality, we are more focused than ever on providing exceptional experiences to all of our guests – and that includes evolving those experiences to meet their changing needs,” said Christopher J. Nassetta, president and CEO, Hilton. “We are proud to launch Signia Hilton, which exemplifies our innovative sp

Axonics® Granted Expanded CE Mark Label; First and Only Sacral Neuromodulation System Approved for Use with Full-Body MRI Scans22.2.2019 16:30:00Pressemelding

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, announced today that it has received CE mark approval for 1.5T and 3T full-body magnetic resonance imaging (“MRI”) conditional labeling for the Axonics r-SNM® System. The Axonics r-SNM System is the only implantable SNM system that has received full-body MRI conditional labeling for sale in Europe1. Raymond W. Cohen, Chief Executive Officer of Axonics, said, “Without this labeling, any patient requiring an MRI scan on any body part below the head must have their neurostimulator surgically explanted prior to the MRI scan, resulting in an additional surgery for the patient and additional costs to patients and the healthcare system. This authorization of full-body MRI scans in Europe is another important milestone for Axonics, differentiating our te

Fantastec Joins Forces with Arsenal FC Launching Official Blockchain Collectibles App22.2.2019 14:30:00Pressemelding

Fantastec announced today its first football licensing agreement with Premier League club Arsenal FC for a new blockchain authenticated collectibles app called Fantastec SWAP. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190222005277/en/ Arsenal players appear on Fantastec SWAP in official licensing deal (Graphic: Business Wire) London-based Fantastec is a leading sports fan technology innovator, and its blockchain based ‘SWAP’ app will have broad appeal to global sports fans, gamers and sports card collectors alike. Fantastec SWAP unlocks unique and authentic club content through the app, like player autographs and exclusive footage. With its innovative blockchain technology, fans around the world can now discover, collect and swap officially licensed club collectibles with other fans with complete trust. “Fantastec SWAP is a game-changer for international football fans as well the sports collectibles industry,” commented

Volkswagen Protects Virtual Key Sharing App with Trustonic Application Protection22.2.2019 13:42:00Pressemelding

Volkswagen is working with mobile cyber security leader Trustonic to enable customers to use smartphones to access their vehicles, and to securely share their digital car keys to grant access to others via a smartphone app. Volkswagen is using the Trustonic Application Protection (TAP) platform to secure the mobile app and ensure that sensitive information and key transfer requests are securely displayed to, and approved by, a real authenticated user on a trusted device and not by hackers or malware simulating a user or device. “The smartphone is becoming the vehicle key of the future and our We Connect service is the interface for this today in the new Volkswagen Passat,” comments Alf Pollex, Head of Infotainment and Connected Car at Volkswagen AG. “The user installs the We Connect app on their smartphone which is then authorized via the infotainment system with a Transaction Number. The Mobile Key will be compatible with Android-based Samsung devices. No mobile network connection is

Mundipharma EDO GmbH: US FDA grants Orphan Drug Designation for etoposide toniribate in relapsed/refractory biliary tract cancer22.2.2019 13:30:00Pressemelding

Mundipharma EDO GmbH, part of the Mundipharma network of independent associated companies, and Imbrium Therapeutics L.P., an operating subsidiary of Purdue Pharma L.P., today announced that the US FDA has granted Orphan Drug Designation (ODD) to etoposide toniribate for the treatment of relapsed/refractory biliary tract cancer, also known as cholangiocarcinoma.3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190222005126/en/ Biliary tract cancer is a rare tumour with approximately 8,000 patients diagnosed in the US every year and 10,571 in Europe.4,5 The FDA grants ODD status to medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US. Radical surgery is the only curative treatment for biliary tract cancer but, in most cases, the cancer is inoperable. Patients who fail first-line chemotherapy have limited treatment options and the standard of